Cisco press release ( CSCO ): Q3 Non-GAAP EPS of $1.06 beats by $0.02 . Revenue of $15.84B (+11.9% Y/Y) beats by $280M . Remaining Performance Obligations (RPO) -- $43.5 billion, up 4% in total. Product RPO was up 6%, of which long-term RPO was $11.7 billion, up 6%. Services RPO was up 2%. Q4 FY 2026 Guidance (1) : Revenue: $16.7 billion to $16.9 billion vs consensus of $15.82B Earnings per Share:...
Cisco press release ( CSCO ): Q3 Non-GAAP EPS of $1.06 beats by $0.02 . Revenue of $15.84B (+11.9% Y/Y) beats by $280M . Remaining Performance Obligations (RPO) -- $43.5 billion, up 4% in total. Product RPO was up 6%, of which long-term RPO was $11.7 billion, up 6%. Services RPO was up 2%. Q4 FY 2026 Guidance (1) : Revenue: $16.7 billion to $16.9 billion vs consensus of $15.82B Earnings per Share: GAAP: $0.80 to $0.85; Non-GAAP: $1.16 to $1.18 vs consensus of $1.07 FY 2026 Guidance (1) : Revenue: $62.8 billion to $63.0 billion vs consensus of $61.60B Earnings per Share: GAAP: $3.16 to $3.21; Non-GAAP: $4.27 to $4.29 vs consensus of $4.16 Shares +2.7% AH. More on Cisco S&P 500: Everyone Is Now An Earnings Expert, And A Quick Look At Cisco's Expected Earnings Cisco Q3 Earnings Preview: Margin Focus As Shares Trade Near Highs Cisco: The AI Top-Line Boom Can't Hide The Free Cash Flow Problem Cisco options market pricing 8% post-earnings move Cisco Q3 preview: AI infrastructure demand, data center growth take center stage
STAAR Surgical press release ( STAA ): Q1 Non-GAAP EPS of $0.48 beats by $0.40 . Revenue of $93.5M (+119.5% Y/Y) beats by $14.78M . Net sales excluding China of $46.1 million, up 6.0% Y/Y Gross margin at 73.6% vs. 65.8% a year ago Net income of $5.2 million or $0.10 per diluted share, compared to a net loss of $(54.2) million or $(1.10) per diluted share a year ago More on STAAR Surgical STAAR Sur...
STAAR Surgical press release ( STAA ): Q1 Non-GAAP EPS of $0.48 beats by $0.40 . Revenue of $93.5M (+119.5% Y/Y) beats by $14.78M . Net sales excluding China of $46.1 million, up 6.0% Y/Y Gross margin at 73.6% vs. 65.8% a year ago Net income of $5.2 million or $0.10 per diluted share, compared to a net loss of $(54.2) million or $(1.10) per diluted share a year ago More on STAAR Surgical STAAR Surgical: Q1 Preliminary Revenues Justify Decision To Reject Alcon Bid STAAR Surgical: Despite Promises Of Improvement, Investors Should Stay Cautious STAAR Surgical Company (STAA) Q4 2025 Earnings Call Transcript STAAR Surgical Q1 2026 Earnings Preview STAAR Surgical surges as Canaccord Genuity raises to Buy on Q1 sales
Piper Sandler’s Chief Market Technician Craig Johnson walked onto CNBC’s Morning Call Sheet with a message for anyone planning to trade today’s Trump-Xi headlines: keep your expectations in check. Asked how the recent AI and tech rally sets markets up for the summit, Johnson said, “I think the Trump-Xi meeting is going to be probably ... NVIDIA, Boeing, Deere: 3 Stocks With the Most to Gain From T...
Piper Sandler’s Chief Market Technician Craig Johnson walked onto CNBC’s Morning Call Sheet with a message for anyone planning to trade today’s Trump-Xi headlines: keep your expectations in check. Asked how the recent AI and tech rally sets markets up for the summit, Johnson said, “I think the Trump-Xi meeting is going to be probably ... NVIDIA, Boeing, Deere: 3 Stocks With the Most to Gain From Trump’s Beijing Summit
Allogene Therapeutics press release ( ALLO ): Q1 GAAP EPS of -$0.18 beats by $0.01 . General and administrative expenses were $14.1 million for the first quarter of 2026, which includes $5.6 million of non-cash stock-based compensation expense. The Company had $266.9 million in cash, cash equivalents, and investments as of March 31, 2026. More on Allogene Therapeutics Allogene Therapeutics, Inc. (...
Allogene Therapeutics press release ( ALLO ): Q1 GAAP EPS of -$0.18 beats by $0.01 . General and administrative expenses were $14.1 million for the first quarter of 2026, which includes $5.6 million of non-cash stock-based compensation expense. The Company had $266.9 million in cash, cash equivalents, and investments as of March 31, 2026. More on Allogene Therapeutics Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma - Slideshow Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL Allogene Therapeutics Q1 2026 Earnings Preview Allogene Therapeutics prices $175M stock offering at $2 per share
Aquestive Therapeutics press release ( AQST ): Q1 GAAP EPS of -$0.07 beats by $0.07 . Revenue of $14.4M (+65.5% Y/Y) beats by $3.5M . Non-GAAP adjusted EBITDA loss was $1.7 million in the first quarter 2026, compared to non-GAAP adjusted EBITDA loss of $17.6 million in the first quarter 2025. Cash and cash equivalents were $110.7 million as of March 31, 2026. 2026 Outlook Aquestive's full-year 202...
Aquestive Therapeutics press release ( AQST ): Q1 GAAP EPS of -$0.07 beats by $0.07 . Revenue of $14.4M (+65.5% Y/Y) beats by $3.5M . Non-GAAP adjusted EBITDA loss was $1.7 million in the first quarter 2026, compared to non-GAAP adjusted EBITDA loss of $17.6 million in the first quarter 2025. Cash and cash equivalents were $110.7 million as of March 31, 2026. 2026 Outlook Aquestive's full-year 2026 financial guidance remains unchanged. The Company expects: Guidance Total revenue (in millions) $46 to $50 Non-GAAP adjusted EBITDA loss (in millions) $35 to $30 Click to enlarge More on Aquestive Therapeutics Aquestive Therapeutics: Post-CRL Risk, Timeline, And Valuation Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript Aquestive Therapeutics Q1 2026 Earnings Preview Aquestive plans 75-rep Anaphylm launch and targets $46M–$50M in 2026 revenue while doubling medical affairs
Four Australian men have given new meaning to the term “ bricked printers .” According to a press release from the Australian Federal Police (AFP) and Australian Border Force (ABF) today, three men have been sentenced for trying to use five printers to smuggle 22.4 kg (49.4 pounds) of cocaine into Australia. In 2019, Australian news outlets reported that the printers were Xerox brand and that the ...
Four Australian men have given new meaning to the term “ bricked printers .” According to a press release from the Australian Federal Police (AFP) and Australian Border Force (ABF) today, three men have been sentenced for trying to use five printers to smuggle 22.4 kg (49.4 pounds) of cocaine into Australia. In 2019, Australian news outlets reported that the printers were Xerox brand and that the drugs had a street value of approximately 9.3 million AUD to over 12.4 million AUD ($6.7 million to over $9 million). Read full article Comments
Cathie Wood, CEO of Ark Investment Management, is facing criticism online over Ark Innovation ETF's (ARKK) recent losses. Bullseye American Ingenuity Fund portfolio manager Adam Johnson shares his thoughts with Yahoo Finance's Josh Lipton.
Cathie Wood, CEO of Ark Investment Management, is facing criticism online over Ark Innovation ETF's (ARKK) recent losses. Bullseye American Ingenuity Fund portfolio manager Adam Johnson shares his thoughts with Yahoo Finance's Josh Lipton.
In trading on Wednesday, shares of Global Water Resources Inc (Symbol: GWRS) entered into oversold territory, changing hands as low as $6.55 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measur
In trading on Wednesday, shares of Global Water Resources Inc (Symbol: GWRS) entered into oversold territory, changing hands as low as $6.55 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measur
In trading on Wednesday, shares of Genesis Energy L.P. (Symbol: GEL) entered into oversold territory, changing hands as low as $15.55 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momen
In trading on Wednesday, shares of Genesis Energy L.P. (Symbol: GEL) entered into oversold territory, changing hands as low as $15.55 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momen
In trading on Wednesday, shares of Safehold Inc (Symbol: SAFE) crossed below their 200 day moving average of $14.82, changing hands as low as $14.59 per share. Safehold Inc shares are currently trading off about 4.1% on the day. The chart below shows the one year performance o
In trading on Wednesday, shares of Safehold Inc (Symbol: SAFE) crossed below their 200 day moving average of $14.82, changing hands as low as $14.59 per share. Safehold Inc shares are currently trading off about 4.1% on the day. The chart below shows the one year performance o
At Holdings Channel, we have reviewed the latest batch of the 70 most recent 13F filings for the 03/31/2026 reporting period, and noticed that Blackrock Inc (Symbol: BLK) was held by 29 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good id
At Holdings Channel, we have reviewed the latest batch of the 70 most recent 13F filings for the 03/31/2026 reporting period, and noticed that Blackrock Inc (Symbol: BLK) was held by 29 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good id
In trading on Wednesday, shares of the VanEck Environmental Services ETF (Symbol: EVX) crossed below their 200 day moving average of $39.28, changing hands as low as $39.05 per share. VanEck Environmental Services shares are currently trading off about 0.7% on the day. The cha
In trading on Wednesday, shares of the VanEck Environmental Services ETF (Symbol: EVX) crossed below their 200 day moving average of $39.28, changing hands as low as $39.05 per share. VanEck Environmental Services shares are currently trading off about 0.7% on the day. The cha
In trading on Wednesday, shares of the SPDR S&P China ETF (Symbol: GXC) crossed above their 200 day moving average of $98.84, changing hands as high as $100.21 per share. SPDR S&P China shares are currently trading up about 2.8% on the day. The chart below shows the on
In trading on Wednesday, shares of the SPDR S&P China ETF (Symbol: GXC) crossed above their 200 day moving average of $98.84, changing hands as high as $100.21 per share. SPDR S&P China shares are currently trading up about 2.8% on the day. The chart below shows the on
In trading on Wednesday, shares of TIM S.A. (Symbol: TIMB) crossed below their 200 day moving average of $23.02, changing hands as low as $22.37 per share. TIM S.A. shares are currently trading off about 3.2% on the day. The chart below shows the one year performance of TIMB s
In trading on Wednesday, shares of TIM S.A. (Symbol: TIMB) crossed below their 200 day moving average of $23.02, changing hands as low as $22.37 per share. TIM S.A. shares are currently trading off about 3.2% on the day. The chart below shows the one year performance of TIMB s
Omeros press release ( OMER ): Q1 Non-GAAP EPS of -$0.24 beats by $0.15 . Revenue of $9.89M beats by $5.78M . Commercial distribution and sales of YARTEMLEA commenced in January 2026. Gross product sales for the three months ended March 31, 2026 were $11.1 million, with net sales of $9.9 million. Revenue for the period reflects sales of YARTEMLEA to U.S. wholesalers. More on Omeros Omeros: Making ...
Omeros press release ( OMER ): Q1 Non-GAAP EPS of -$0.24 beats by $0.15 . Revenue of $9.89M beats by $5.78M . Commercial distribution and sales of YARTEMLEA commenced in January 2026. Gross product sales for the three months ended March 31, 2026 were $11.1 million, with net sales of $9.9 million. Revenue for the period reflects sales of YARTEMLEA to U.S. wholesalers. More on Omeros Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript Omeros: Yartemlea Can Own The Label And Still Split The Market Omeros rises as Novo deal boosts Q4 earnings Omeros expects YARTEMLEA to be financially self-sustaining in 2026 and targets positive cash flow in 2027
Amdocs press release ( DOX ): Q2 Non-GAAP EPS of $1.78 beats by $0.02 . Revenue of $1.17B (+3.5% Y/Y) in-line. Third Quarter Fiscal Year 2026 Outlook In millions, except per share data Q3 - 2026 Revenue $ 1,155-$1,195 vs consensus of $1.18B GAAP Diluted earnings per share $ 1.39-$1.47 Non-GAAP Diluted earnings per share $ 1.81-$1.87 vs consensus of $1.89 Click to enlarge
Amdocs press release ( DOX ): Q2 Non-GAAP EPS of $1.78 beats by $0.02 . Revenue of $1.17B (+3.5% Y/Y) in-line. Third Quarter Fiscal Year 2026 Outlook In millions, except per share data Q3 - 2026 Revenue $ 1,155-$1,195 vs consensus of $1.18B GAAP Diluted earnings per share $ 1.39-$1.47 Non-GAAP Diluted earnings per share $ 1.81-$1.87 vs consensus of $1.89 Click to enlarge
Bloomberg’s Caroline Hyde and Ed Ludlow discuss what to expect from the highly anticipated meeting between President Trump and China's Xi Jinping, as Nvidia CEO Jensen Huang gets added to the trip last minute. Plus, Anthropic is looking to raise at least $30 billion in fresh financing at a valuation of more than $900 billion, in what could be its largest funding round yet. And, we speak with Andur...
Bloomberg’s Caroline Hyde and Ed Ludlow discuss what to expect from the highly anticipated meeting between President Trump and China's Xi Jinping, as Nvidia CEO Jensen Huang gets added to the trip last minute. Plus, Anthropic is looking to raise at least $30 billion in fresh financing at a valuation of more than $900 billion, in what could be its largest funding round yet. And, we speak with Anduril CEO Brian Schimpf as the company hits a $61 billion valuation in its latest funding round. (Source: Bloomberg)
Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026
Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026